TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Biochemical Antigen | SMARCA2 Full-Length & ATPase Domain Proteins High purity (>95%), Endotoxin <1EU/μg, Sequence Verified, HEK293 Expressed (Native Glycosylation), Theoretical MW confirmed. |
View SMARCA2 Products |
| Gene Delivery | SMARCA2 Promise-ORF Lentivirus Full-length ORF for stable cell line construction and synthetic lethality validation. |
View SMARCA2 Products |
| Detection Antibody | Anti-SMARCA2 (Research Grade) For Western Blot, Co-IP, and ternary complex detection. Sequence of clone verified. |
View SMARCA2 Products |
| Validator | SMARCA2 siRNA Set For knockdown and synthetic lethality verification. Sequence-verified targets. |
View SMARCA2 Products |
| Synthetic Lethality Pair | SMARCA4 (BRG1) Essential for selectivity profiling and counter-screening; 80% homology requires matched reagents. |
View SMARCA4 Products |
| Complex Component | SMARCB1 (INI1) Core SWI/SNF subunit for complex assembly and protein-protein interaction assays. |
View SMARCB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Activity & Binding Affinity | Full-length SMARCA2 with intact ATPase domain (>95% purity, Sequence Verified by Mass Spec, Endotoxin <1EU/μg) |
| SMARCA4 Selectivity (High Homology) | Matched pair of SMARCA2 & SMARCA4 proteins from same HEK293 batch; sequence-verified distinct epitopes for antibody selectivity testing |
| PROTAC Ternary Complex Formation | High-concentration protein formulation (>5 mg/mL) suitable for crystallography and SPR/ITC analysis |
| False Positives in Cellular Assays | Validated siRNA included for specificity checks; Lentivirus for stable expression controls |
Key Functional Domains and Mutations
SMARCA2 (BRM) contains several conserved functional domains essential for chromatin remodeling:
- QLQ domain: Involved in protein-protein interactions, important for SWI/SNF complex assembly.
- HSA (Helicase/SANT-Associated) domain: Mediates interactions with other complex components.
- Helicase ATP-binding domain: Core enzymatic domain responsible for ATP hydrolysis and chromatin remodeling activity.
Key mutations identified in patients:
- VAR_085660: Found in a patient with non-specific intellectual disability syndrome; likely pathogenic.
- VAR_085661: Found in a patient with non-specific intellectual disability syndrome; likely pathogenic.
- VAR_085662: In BIS (Coffin-Siris syndrome), affecting the SWI/SNF complex function.
These mutations highlight the critical role of SMARCA2 in neurodevelopment and tumor suppression.
Global Clinical Landscape & Future Outlook
The race for SMARCA2 therapeutics is intensifying, with major players shifting focus from traditional small molecule inhibitors to targeted protein degraders (PROTACs/Molecular Glues). First-generation PROTACs (e.g., CFT-1945) are entering Phase I trials for SMARCA4-mutant NSCLC, while the field rapidly pivots toward paralog-selective degradation and combination strategies to circumvent acquired resistance. With SMARCA4 mutations prevalent in lung, ovarian, and pancreatic cancers, synthetic lethality biomarkers position SMARCA2 as a dominant oncology target. Moreover, patient-derived mutations in SMARCA2 (e.g., those causing intellectual disability and BIS) highlight the need for isoform-selective therapies to avoid on-target toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC Degraders | C4 Therapeutics, Cascade Therapeutics, Prelude Therapeutics | SMARCA4-mutant NSCLC, Small Cell Ovarian Carcinoma | Ternary Complex Assembly (Need high-purity full-length protein & E3 ligase components) |
| ATPase Inhibitors (Dual/Single) | Foghorn Therapeutics, Bayer, Foresight Diagnostics | SMARCB1-deficient Tumors, Solid Tumors | Enzymatic Activity & Selectivity (Need active ATPase domain vs SMARCA4 counter-screen) |
| Molecular Glues | Undisclosed Biotech Partnerships | SWI/SNF Dysregulated Cancers | Protein-Protein Interaction Disruption (Need SMARCB1 complex reconstitution) |
| Synthetic Lethal Combinations | Academic & Industry Consortia | Pancreatic, SMARCB1-null tumors | Rescue / Knockdown Assay (Need ORF lentivirus + siRNA validators) |
Live SMARCA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Related Target Note
Beyond SMARCA4 and SMARCB1, ARID1A is a core SWI/SNF complex subunit frequently co-mutated in solid tumors, making it an important target for combination studies. TarMart provides ARID1A reagents (see View ARID1A Products).